Roquefort Therapeutics (LON:ROQ) Stock Price Down 11.1% – What’s Next?

Roquefort Therapeutics plc (LON:ROQ) shares traded down 11.1% on Friday . The company traded as low as GBX 1.20 and last traded at GBX 1.20. 219,883 shares were traded during mid-day trading, a decline of 81% from the average session volume of 1,157,323 shares. The stock had previously closed at GBX 1.35.

Roquefort Therapeutics Stock Performance

The firm has a market capitalization of £1.96 million, a price-to-earnings ratio of -1.90 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The stock’s 50-day moving average is GBX 1.44 and its 200-day moving average is GBX 1.64.

Insider Activity at Roquefort Therapeutics

In other news, insider Dr Darrin Disley purchased 5,000,000 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was bought at an average cost of GBX 170 per share, for a total transaction of £8,500,000. Insiders own 23.53% of the company’s stock.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.